The FDA has accepted Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the primary and solely subcutaneous, chemo-free therapy for sufferers with EGFR-mutated non-small cell lung most...
Lively Biotech has obtained optimistic suggestions from regulators on a protocol modification to its ongoing proof-of-concept scientific trial evaluating tasquinimod in sufferers with myelofibrosis, a...
Final yr introduced notable developments in blood most cancers remedy and analysis, highlighting a number of myeloma, lymphoma, leukemia and myelodysplastic syndromes....
Amongst sufferers with gastric or gastroesophageal junction (GEJ) adenocarcinoma, these with a baseline ECOG efficiency standing of 1 skilled worsened patient-reported outcomes...
The U.S. Meals and Drug Administration (FDA) has granted orphan drug designation to CK0804, an investigational regulatory T cell remedy developed by...
